BIOXYTRAN, INC Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Bioxytran performed this past year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do?

Bioxytran is a clinical-stage pharmaceutical company currently in the high-stakes research phase. They develop sugar-based drugs designed to block viruses and treat conditions involving low oxygen and brain damage. They operate through four subsidiaries: the parent company, ProLectin Therapeutics (drug development), Pharmalectin (patent management), and research operations in India that help keep trial and lab costs low.

2. Financial performance

Because they are still in the research phase, the company earned $0 in revenue for the year ending December 31, 2025. As of April 2026, they had about 113.4 million shares outstanding. Operating expenses totaled $2.8 million, primarily for research and administration. They fund operations by selling stock and converting debt into shares. Last year, they spent between $200,000 and $250,000 per month to maintain operations.

3. Major wins and challenges

• The Science: Their lead drug, "ProLectin-M," showed promise in a Phase 2a COVID-19 trial. Patients taking the drug cleared the virus in 3 days, compared to 7 days for those on a placebo. This suggests the drug significantly shortens the time a patient carries the virus.
• The Challenge: As a small, emerging business, the company must constantly raise cash to survive. With cash balances often dipping below $500,000, they require regular cash injections to avoid running out of money.

4. Financial health

Bioxytran is in a "burn" phase, spending more than they make to develop new medical treatments. They are a "smaller reporting company" with a limited financial cushion. Their survival depends on their "runway"—how much cash they have versus how fast they spend it. Currently, their debts exceed their assets, meaning they need new financing to continue operations over the next year.

5. Key risks

• Dilution: Because they frequently issue new shares to pay for operations, your "slice of the pie" shrinks. Converting debt into stock increases the total share count, which reduces the potential value of your individual shares.
• The "All-or-Nothing" Nature of Science: Their products use new, unproven technology. If their clinical trials fail or they do not receive government approval, they may have no product to sell, which could make the stock worthless.
• Competition: The medical field moves fast. Larger competitors with massive budgets—like Pfizer or Merck—could release a better or cheaper version, which would impact the market for Bioxytran’s products.

6. Future outlook

The company is focused on moving its drug candidates through the regulatory process, specifically targeting key milestones for ProLectin-M. They believe their "Galectin" technology will be their breakthrough. However, they have noted that they must raise more money, which will likely involve selling more stock or taking on debt, potentially leading to further dilution for current shareholders.

Investor Takeaway: Bioxytran is a high-risk, speculative play. Because they have no revenue and rely on selling shares to fund their research, your investment is essentially a bet on the success of their clinical trials. If you are considering this stock, keep a close eye on their cash levels and any announcements regarding new stock offerings, as these will directly impact the value of your holdings.